Patrick Zenner joins Par’s board of directors
WOODCLIFF LAKE, N.J. Generic drug maker Par Pharmaceutical Cos. has appointed a former Roche executive to its board of directors, Par said Thursday.
Par announced the appointment of Patrick Zenner, whom it also appointed to two executive committees. Zenner retired in 2001 from Hoffman-La Roche North America, where he had worked for 32 years, including eight years as president and CEO. Currently, he is board chairman of ArQule and Exact Sciences Corp. and a director of West Pharmaceutical Services, as well as a trustee of Creighton University.
“I am very pleased to welcome an executive of Pat’s caliber to our board,” Par CEO Patrick LePore said. “He has a detailed knowledge of the pharmaceutical industry and has extensive board experience.”
Independent pharmacies tap into long-term care market with new center
DENVER Healthcare services company Cardinal Health will work with the American Society of Consultant Pharmacies to help independent retail pharmacies tap into the long-term care market, Cardinal said Thursday.
According to statistics from 2008, the number of adults in the United States needing nursing home or assisted living care is expected to be 20 million by 2050. Officially launched at Cardinal’s Retail Business Conference in Denver this week, the Long Term Care Specialized Care Center will give independents access to long-term care field specialists, discounts on the ASCP’s policy and procedure manuals and continuing education courses and market analyses.
“Many independent pharmacists want to start serving the high-growth long-term care market, but doing so requires a specialized knowledge base and skill set,” Cardinal VP market management and product development Jay Williams said. “That’s why we’ve partnered with ASCP – the recognized expert in geriatric pharmacotherapy – to provide our customers with the education and building blocks they need to immediately start serving the medication needs of the long-term care facilities in their communities.”
GSK joins the National Pharmaceutical Council
WASHINGTON British drug maker GlaxoSmithKline is the latest company to join health policy research organization the National Pharmaceutical Council, the NPC announced Thursday.
Established in 1953, the NPC sponsors and conducts scientific analyses of the use of drugs with support from drug companies. GlaxoSmithKline SVP private, public and institutional customers Jack Bailey will serve as the company’s representative on the NPC’s board of directors.
“As the nation moves forward with the implementation of healthcare reform, NPC’s research provides policy makers and implementers with keen insight on comparative effectiveness research and health-and-wellness issues,” Bailey said. “I welcome the opportunity to work with NPC and its staff as they move forward with these and other research areas impacting the pharmaceutical industry.”